BLOG

IV Infusion vs. Local Injection for Stem Cell Therapy in Japan

Published 2026.10.18 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Regenerative medicine, particularly adipose-derived stem cell therapy, is gaining attention as a therapeutic option for addressing various health concerns related to aging and tissue damage. A common question that arises is about the method of administration: why are stem cells often delivered through a systemic intravenous (IV) infusion rather than a direct local injection into a specific area of concern? This article explores the scientific rationale behind the systemic approach used in Japan, focusing on the unique capabilities of mesenchymal stem cells (MSCs).

Why Systemic IV Infusion is a Key Approach in Stem Cell Therapy

The primary reason for using IV infusion in adipose-derived stem cell therapy is to leverage a natural biological process known as the “homing effect.” When administered into the bloodstream, mesenchymal stem cells have been reported to circulate throughout the body and navigate towards sites of inflammation or tissue damage. This systemic approach allows the cells to potentially reach multiple areas that could benefit from their regenerative signaling, not just a single, targeted location. It is a strategy that aims to support the body’s overall repair mechanisms, which can be particularly relevant for age-related or systemic conditions.

Local Injection vs. IV Infusion: Understanding the Difference

To understand the preference for IV infusion, it’s helpful to compare it with local injection. A local injection delivers a high concentration of stem cells directly to a specific site, such as an arthritic knee joint. This can be a logical approach when the problem is clearly localized. However, many challenges associated with aging and chronic conditions are not confined to one spot. Subtle inflammation and cellular damage can exist in various tissues throughout the body, often without causing noticeable symptoms.

A systemic IV infusion, on the other hand, does not presume to know every location that needs support. Instead, it relies on the inherent ability of MSCs to detect distress signals (inflammatory cytokines and chemokines) released by injured cells. By introducing the cells into the circulatory system, the therapy allows them to travel widely and accumulate where they are needed most. This makes it a comprehensive approach aimed at addressing both identified and unidentified areas of concern.

The Science of the “Homing Effect” in Mesenchymal Stem Cells

The “homing effect” is a well-documented phenomenon in stem cell research. When tissues are damaged or inflamed, they release specific chemical signals into the bloodstream. Mesenchymal stem cells are equipped with surface receptors that can recognize these signals. Upon detection, the MSCs are prompted to stop, adhere to the blood vessel wall, and migrate through it into the surrounding tissue to reach the source of the signals. Numerous preclinical and clinical studies have explored this mechanism, suggesting it is a key factor in the potential therapeutic action of systemically administered MSCs.

Beyond simply traveling to a site, once MSCs arrive, they are thought to exert their influence primarily through paracrine effects. This means they release a variety of bioactive molecules, such as growth factors and anti-inflammatory proteins, that can help calm inflammation, modulate the local immune response, and support the repair processes of the resident cells. Therefore, the goal of a stem cell therapy IV infusion is not necessarily to replace damaged cells, but to create a more favorable environment for the body’s own healing capabilities.

Potential Advantages of a Systemic Approach

Choosing a systemic route of administration offers several potential advantages in the context of regenerative medicine:

Addressing Multiple Sites: It allows for the potential to address chronic, low-grade inflammation or damage in various parts of the body simultaneously, which a single local injection cannot do.
Supporting Systemic Health: The approach is aligned with managing age-related concerns that are often systemic in nature, such as declining stamina, slower recovery, and vascular health.
Immunomodulatory Effects: Circulating MSCs have been reported to interact with immune cells and help balance the immune system, which can be beneficial for conditions involving excessive inflammation.
Less Invasive for Multiple Issues: For individuals with concerns in multiple joints or tissues, a single IV infusion may be a less invasive option than multiple separate injections.

Important Considerations for Stem Cell Therapy in Japan

It is crucial to approach stem cell therapy with a clear understanding of what it entails. This treatment is not a guaranteed cure, and individual outcomes can vary. The decision to undergo therapy should be made after a thorough consultation with a physician who can assess your specific health condition, medical history, and suitability for the treatment.

In Japan, regenerative medicine treatments like adipose stem cell therapy are provided under the Act on the Safety of Regenerative Medicine. This requires medical institutions to submit their treatment plans to the Ministry of Health, Labour and Welfare for review, ensuring that safety management and cell processing standards are met. This therapy is considered an elective treatment and is not covered by public health insurance. A physician’s evaluation is necessary to determine eligibility, and patients should be fully informed about the potential risks, side effects, expected number of treatments, and total costs before proceeding.

Learn More About Your Options in Osaka

At Grand Green Osaka Umekita Clinic, we provide adipose-derived stem cell therapy using the systemic IV infusion approach. We believe this method aligns with a holistic view of health and aging, aiming to support the body’s innate capacity for repair. Our process is conducted in compliance with Japan’s regulatory standards for regenerative medicine.

If you are exploring options for regenerative medicine in Osaka and wish to understand if this approach is suitable for you, we encourage you to seek professional medical advice. For more detailed information on our Adipose-Derived Stem Cell Therapy, including the treatment process, potential risks, and associated fees, please visit our dedicated information page.

Learn more about Adipose-Derived Stem Cell Therapy at Umekita Clinic

Conclusion: A Systemic View on Healing and Regeneration

The use of IV infusion for adipose stem cell therapy is a deliberate choice based on the scientific understanding of the mesenchymal stem cells’ homing effect. Rather than limiting the potential benefits to a single point, this systemic approach allows these intelligent cells to travel to where they are needed, offering a broader, more comprehensive way to support tissue health and combat inflammation. As with any medical treatment, a detailed discussion with a qualified physician is the essential first step to determine the most appropriate path for your individual health goals.

Stem Cell Therapy: IV Infusion vs. Local Injection

Local Injection

Targets a specific, single site
For clearly localized problems
Misses other areas of concern

IV Infusion (Systemic)

Circulates throughout the body
Cells 'home in' on damage signals
Addresses multiple sites at once

This diagram simplifies the concepts discussed in the article for illustrative purposes

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›